Intec Pharma (NASDAQ:NTEC) posted its earnings results on Friday. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.03, MarketWatch Earnings reports.
Intec Pharma stock traded up $0.01 during midday trading on Friday, hitting $5.89. The company’s stock had a trading volume of 126,488 shares, compared to its average volume of 130,876. Intec Pharma has a 1-year low of $3.55 and a 1-year high of $7.50. The stock has a market capitalization of $193.02 million, a price-to-earnings ratio of -3.57 and a beta of 0.71.
A number of analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Intec Pharma from a “buy” rating to a “hold” rating in a research note on Thursday. HC Wainwright set a $16.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a research note on Wednesday, October 24th. Roth Capital assumed coverage on shares of Intec Pharma in a research note on Friday, October 5th. They set a “buy” rating and a $8.50 target price for the company. Finally, Oppenheimer set a $15.00 target price on shares of Intec Pharma and gave the stock a “buy” rating in a research note on Sunday, September 30th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $11.40.
TRADEMARK VIOLATION WARNING: “Intec Pharma (NTEC) Releases Earnings Results, Beats Expectations By $0.03 EPS” was reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://weekherald.com/2018/11/10/intec-pharma-ntec-releases-earnings-results-beats-expectations-by-0-03-eps.html.
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.